Medication Guide App

NanoBio to Announce Key Clinical and Preclinical Data on Its Topical Anti-infective Lotions at AAD 2009

ANN ARBOR, Mich., March 02, 2009 /PRNewswire/ -- NanoBio Corp. announced today that it will present compelling new data highlighting key clinical and preclinical milestones in the development of its novel topical treatments for herpes labialis, onychomycosis and tinea capitis. The new data will be delivered in five presentations during the 2009 meeting of the American Academy of Dermatology in San Francisco, March 6-9, 2009.

In addition to the oral poster presentations listed below, the presentations will be available electronically at the kiosks provided by the AAD during the conference. NanoBio will also sponsor corporate booth # 5284, where information on the company's development programs for acne, herpes and antifungal products will be available.

Oral Poster Presentations

Poster # P2411, 10:20 a.m. -- Antifungal Activity and Mechanism of Action of NB-002, a Novel Topical Antifungal, Against the Major Pathogens of Onychomycosis

Poster # P2423, 12:20 p.m. -- Antifungal Activity of NB-002, a Topical Nanoemulsion, Against Rare Fungal Pathogens of Onychomycosis

Poster # P2505, 2:00 p.m. -- Investigator Assessed Time to Healing in a Randomized, Double-Blind, Vehicle-Controlled Trial of a Novel Antiviral Nanoemulsion (NB-001) for Recurrent Herpes Labialis

Poster # P2517, 4:00 p.m. -- Safety, Tolerability and Pharmacokinetics of Topical NB-001 (0.1%, 0.3% and 0.5%) for the Treatment of Recurrent Herpes Labialis

Poster # P2114, 10:40 a.m. -- A Randomized, Double-Blind, Vehicle-Controlled Trial of Novel Topical Antifungal Nanoemulsion (NB-002) in Subjects With Distal Subungual Onychomycosis

NanoBio(R) Corp. is a privately held biopharmaceutical company focused on developing and commercializing dermatological products, anti-infective treatments and intranasal vaccines derived from its patented NanoStat(TM) technology platform. The company's lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), acne, cystic fibrosis and a broad platform of intranasal vaccines. The company's headquarters and laboratory facilities are located in Ann Arbor, Michigan.

CONTACT: John Coffey, Vice President, Business Development, NanoBio Corp.,+1-734-302-9107, john.coffey@nanobio.com

Web site: http://www.NanoBio.com/

Terms and conditions of use apply
Copyright © 2009 PR Newswire Association LLC. All rights reserved.
A United Business Media Company

Posted: March 2009

View comments

Hide
(web1)